Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial.
Adult
Biomarkers
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Glucagon-Like Peptide 1
Humans
Hypoglycemic Agents
/ therapeutic use
Liraglutide
/ therapeutic use
Middle Aged
Obesity
/ complications
Sitagliptin Phosphate
/ therapeutic use
Stem Cells
Vascular Endothelial Growth Factor A
liraglutide
randomized active-comparator trial
sitagliptin
stromal cell-derived factor-1-alpha
type 2 diabetes
vascular endothelial growth factor
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
23
01
2021
received:
03
11
2020
accepted:
04
02
2021
pubmed:
11
2
2021
medline:
10
7
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
The mechanisms behind the beneficial cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) compared with dipeptidyl peptidase-4 inhibitors (DPP4is) remain largely unknown, despite both targeting the incretin pathway to improve glycaemic control. In these prespecified secondary analyses of the LYDIA trial, we examined the impact of the GLP-1RA liraglutide (1.8 mg once-daily) and the DPP4i sitagliptin (100 mg once-daily) on circulating cardiovascular biomarkers associated with atherosclerotic risk, including circulating progenitor cells (CPCs). LYDIA was a 26-week, randomized, active-comparator trial in 61 adults with type 2 diabetes and obesity (mean ± SD: age 43.8 ± 6.5 years, body mass index 35.3 ± 6.4 kg/m
Substances chimiques
Biomarkers
0
Dipeptidyl-Peptidase IV Inhibitors
0
Hypoglycemic Agents
0
Vascular Endothelial Growth Factor A
0
Liraglutide
839I73S42A
Glucagon-Like Peptide 1
89750-14-1
Sitagliptin Phosphate
TS63EW8X6F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1409-1414Subventions
Organisme : Department of Health
ID : CDF-2014-07-045
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab. 2019;21(11):2576-2580.
Deacon CF. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes Obes Metab. 2018;20(S1):34-46.
Webb DR, Htike ZZ, Swarbrick DJ, et al. A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes Obes Metab. 2020;22:1187-1196.
Patel RS, Li Q, Ghasemzadeh N, et al. Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease. Circ Res. 2015;116(2):289-297.
Rigato M, Avogaro A, Fadini GP. Levels of circulating progenitor cells, cardiovascular outcomes and death: a meta-analysis of prospective observational studies. Circ Res. 2016;118(12):1930-1939.
Liu C, Liu Y, He J, et al. Liraglutide increases VEGF expression via CNPY2-PERK pathway induced by hypoxia/reoxygenation injury. Front Pharmacol. 2019;10:789.
Petyunina O, Kopytsya M, Kuznetsov I, et al. Prognostication of clinical outcomes after STEMI: the role of vascular endothelial growth factor-A. Georgian Med News. 2018;279:79-86.
Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol. 2020;11:178.
Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858-864.
Li P, Tang Z, Wang L, Feng B. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice. Mol Med Rep. 2017;16(3):3421-3426.
Kajikawa M, Maruhashi T, Hidaka T, et al. Effect of saxagliptin on endothelial function in patients with type 2 diabetes: a prospective multicenter study. Sci Rep. 2019;9(1):10206.
Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33(7):1607-1609.
Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α(1-67) in patients with type 2 diabetes. Diabetes Care. 2017;40(8):1073-1081.
De Ciuceis C, Agabiti-Rosei C, Rossini C, et al. Microvascular density and circulating endothelial progenitor cells before and after treatment with incretin mimetics in diabetic patients. High Blood Press Cardiovasc Prev. 2018;25(4):369-378.
Morishita T, Uzui H, Ikeda H, et al. Effects of sitagliptin on the coronary flow reserve, circulating endothelial progenitor cells and stromal cell-derived factor-1alpha. Intern Med. 2019;58(19):2773-2781.
Fadini GP, Bonora BM, Cappellari R, et al. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):748-756.
Williams SB, Cusco JA, Roddy M-A, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27(3):567-574.
Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 2000;37(2):87-92.
Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol. 2019;234(6):8286-8294.
Sargeant JA, Brady EM, Zaccardi F, et al. Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials. Diabetologia. 2020;63(8):1516-1520.